AMENDMENTS TO THE CLAIMS

2 .

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended): N-phenyl-2-pyrimidine-amine derivative represented by the following formula (1):

$$R_3$$
 R_2
 R_1
 R_4
 R_5
 R_6
 R_6
 R_7
 R_8
 R_7
 R_8
 R_8
 R_8
 R_9
 R_1
 R_1
 R_2
 R_3
 R_4
 R_5
 R_6
 R_7

and its salt, in which

R₁ represents 3-pyridyl or 4-pyridyl,

R₂ and R₃ each represent hydrogen or lower alkyl,

R₆ or R₇ represents a radical having the following formula (2):

$$-N$$
 $C_{H_2}(X)_n - R_9$ (2)

wherein X represents oxygen or NH, n=0 or 1, and R₉ represents aliphatic having 5 to 10 carbon atoms, or represents 5 to 7 membered saturated or unsaturated monocyclic radical, or bi—or tri-cyclic radical optionally combined with benzene ring, each of which has 1 to 3 hetero atoms selected from a group consisting of nitrogen, oxygen and sulfur, or represents piperazinyl or homopiperazinyl each of which is substituted by lower alkyl piperidine or 4-methylhomopiperazine when n=0, or 4-methylpiperazine when n=1, and

 R_4 , R_5 , R_7 , and R_8 each represent hydrogen, or one or two thereof each represent halogen, lower alkyl, or lower alkoxy when R_6 represents the radical of the above formula (2), or one or two of R_4 , R_5 , R_6 , and R_8 each represent halogen, lower alkyl, or lower alkoxy R_4 represents hydrogen and one or two of R_5 , R_6 , and R_8 each represent halogen, lower alkyl or lower alkoxy, or R_4 represents methyl or methoxy, R_5 , R_6 , and R_8

Reply to Office Action of February 3, 2000

represent hydrogen, and R_9 represents lower alkyl-substituted homopiperazine, when R_7 represents the radical of the above formula (2),

3 .

provided that R_6 or R_7 represents a radical of formula (2) wherein n=0 and R_9 is 4-methylpiperazine, then one or more of R_4 , R_5 , R_7 , and R_8 , or one or more of R_4 , R_5 , R_6 , and R_8 are halogen.

2 (currently amended): The compound of claim 1 wherein

R₁ represents 3-pyridyl,

R₂ and R₃ each represent hydrogen,

R₆ or R₇ represents a radical having the following formula (2):

$$-N \xrightarrow{O} C_{H_2}(X)_{n} R_{s}$$
(2)

wherein X represents oxygen or NH, n=0 or 1, and R₉ represents piperidine, or 4-methylhomopiperazine when n=0, or 4-methylpiperazine when n=1, and R₄, R₅, R₇, and R₈ each represent hydrogen, or one or two thereof each represent fluoro, methyl, or methoxy when R₆ represents the radical of the above formula (2), or one or two of R₄, R₅, R₆, and R₈ each represent fluoro, methyl, or methoxy when R₇ represents the radical of the above formula (2).

3 (original): The compound of claim 1 wherein R_1 represents 3-pyridyl, R_2 , R_3 , R_4 , R_5 , R_7 , and R_8 each represent hydrogen, and R_6 represents the radical of formula (2) wherein n=0 and R_9 represents 4-methylhomopiperazine, or n=1, X represents NH, and R_9 represents 4-methylpiperazine.

4 (original): The compound of claim 1 wherein R_1 represents 3-pyridyl, R_2 and R_3 each represent hydrogen, R_4 represents methyl, R_5 , R_6 and R_8 each represent hydrogen, and R_7 represents the radical of formula (2) wherein n=1, X represents NH, and R_9 represents 4-methylpiperazine.

5 (cancelled).

Application No. 10/806,834 . 4 Docket No.: 59300CIP(71970)

Amendment dated May 3, 2006 Reply to Office Action of February 3, 2006

pharmaceutically acceptable inert carriers.

6 (original): A pharmaceutical composition for the treatment of lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, or cervical cancer, which comprises an effective amount of the compound of formula (1) or its salt as defined in claim 1 as an active ingredient together with

7 (original): The composition of claim 6 which is used as an oral preparation.

8 (original): The composition of claim 6 which is used as an injection.

9 (cancelled).